WHO-led COVAX vaccine scheme agrees new supply deal with India's Serum
They would be produced by Serum under a technology transfer agreement
A research scientist works inside a laboratory of India's Serum Institute, the world's largest maker of vaccines, which is working on vaccines against the coronavirus disease (Covid-19) in Pune, India, May 18, 2020. Picture taken May 18, 2020. REUTERS/Euan Rocha/File Photo/File Photo
India's Serum Institute will supply 1.1 billion doses of Covid-19 vaccines developed by AstraZeneca and Novavax to the COVAX vaccine scheme as part of a new long-term deal, head of the U.N. Children's Fund said on Wednesday.
UNICEF chief Henrietta Fore said the shots would be delivered over a number of years at the cost of about $3 per dose for low- and middle-income countries.
They would be produced by Serum under a technology transfer agreement, she said in a briefing.
Keep updated, follow The Business Standard's Google news channel
The COVAX facility is co-led by GAVI, the World Health Organization, the Coalition for Epidemic Preparedness Innovations and UNICEF.
